An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy
This study discovered a 22-metabolite panel to discriminate patients with csPCa from Be + ciPCa patients when combined with age, PSA, and %fPSA. It may therefore be used as a supportive biomarker to reduce the number of unnecessary biopsies and also to identify novel therapeutic targets in the future.
Authors
- Michael Ladurner (ORCID: https://orcid.org/0000-0003-2396-9175)
- Helmut Klocker (ORCID: https://orcid.org/0000-0001-7732-9443)
- Hannes Neuwirt (ORCID: https://orcid.org/0000-0003-1064-0098)
- Gerhard P. Aigner (ORCID: https://orcid.org/0000-0003-0209-8075)
- Iris E. Eder (ORCID: https://orcid.org/0000-0003-3716-0027)
- Eberhard Steiner (ORCID: https://orcid.org/0009-0006-5798-5746)
- Isabel Heidegger (ORCID: https://orcid.org/0000-0003-1517-5746)
- Diana Drettwan
- T. Ameismeier
- Selina Strathmeyer (ORCID: https://orcid.org/0009-0006-6074-5268)
- Tina Böld
- Helga Hauffe
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Maschinenfabrik Reinhausen (Germany) (DE)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1210/clinem/dgae704
- Citations
- 2
- Primary Topic
- Metabolomics and Mass Spectrometry Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.47